Share Price:

APNASPENAspen Pharmacare Hldgs169000 (0.00%)

Aspen is in a closed period from 1st July 2024 until the publication of the FY2024 results on the JSE SENS platform to be released on the 3rd September 2024.

Regional Overviews

Aspen in Asia

This region is the main contributor to the Group’s Injectables revenue, covering all Asian territories, including China. Active trading subsidiaries are based in China, the Philippines, Taiwan, and Malaysia, while other areas, such as Hong Kong, are supported through distributor partnerships. Additionally, there is a manufacturing site in Hyderabad, India, specialising in new product development.

Key Locations

China
Hong Kong
Malaysia
Philippines
Singapore
Thailand

Overview

Brand Therapeutic category

Arixtra

Antithrombotic agent

Diprivan

General anaesthetic

Fraxiparine

Low molecular weight heparin

Eltroxin

Thyroid hormone replacement

Naropin

Regional anaesthetic

0
Products
Launched

(2023: 3)

0
Product
Recalls
(2023: Nil)
0 %
Average Staff
Turnover

(2023: 22%)

0
Work-related
Facilities

(2023: Nil)

100 *
Sales
Representatives

(2023: 470)

1000 *
Permanent
Employees

(June 2024)

1080 *
Permanent
Employees

(June 2023)

* Excludes acquisition of Sandoz AG China business.

0
Products
Launched

(2022: 3)

Product
Recalls

(2022: Nil)

10 %
Average Staff
Turnover

(2022: 29%)

Work-related
Facilities

(2022: Nil)

410
Sales
Representatives

(2022: 535)

900
Permanent
Employees

(June 2022: 1,166)

Revenue 2024
R’million
2023 (CER)
R’million
Change
%
Commercial Pharmaceuticals

4 100

5 623

(27)

Injectables

3 112

4 790

(35)

Prescription

697

560

24

Over the counter

291

273

7

Manufacturing

Finished dose form

100

122

(18)

Total

4 200

5 745

(27)

Note: Commercial Pharmaceuticals’ revenue is by customer geography and Manufacturing revenue is by place of manufacture.
Contribution to Group revenue (%)
Revenue by segment (%)
  • Propofol market value in May 2024 was RMB2,54 billion, compared to RMB2,74 billion in the prior year. The market value decline is due to the implementation of Volume Based Procurement.
  • Aspen’s Diprivan holds 37% as at May 2024, a decline of 1,97% compared to May 2023.

Source: China IMS CHPA Report, May 2024.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.